Metabolic Signatures for Liver Cancer Diagnosis and Mechanistic Insights: A Large‐Scale, Multicenter Study
Open Access
- 4 October 2026
- journal article
- research article
- Published by Wiley in Advanced Science
- p. e78077
Abstract
The poor prognosis of liver cancer (LC) highlights the urgent need for more effective strategies for early detection. We conducted a large, multicenter study to develop and validate a serum metabolic signature for LC diagnosis. Using high‐throughput nanoparticle‐enhanced laser desorption/ionization mass spectrometry, we profiled serum metabolites from 1,924 participants in discovery cohort recruited across 11 clinical centers and 225 participants in independent external validation cohort from two additional centers. A nine‐metabolite signature combined with alpha‐fetoprotein achieved excellent discriminatory performance, with an AUC of 0.92 in the discovery cohort and 0.93 in the external validation cohort. The combined model also showed good sensitivity for early‐stage LC, reaching 0.85 and 0.78 in the two cohorts, respectively, and performed particularly well for hepatocellular carcinoma, with AUCs of 0.94 and 0.93. Exploratory analyses suggested potential utility for intrahepatic cholangiocarcinoma diagnosis. Mendelian randomization analysis supported a potential causal association between nicotinamide (NAM) levels and LC risk. Functional studies showed that NAM promotes LC cell proliferation, migration, and invasion, through an NAD + /SIRT1‐dependent mechanism that increases HIF1α stability and activates glycolytic and MAPK signaling. Overall, we developed a promising metabolic diagnostic signature for LC and identified NAM‐associated metabolic signaling as a potential contributor to LC progression.Keywords
Funding Information
- National Natural Science Foundation of China (82574179)
This publication has 47 references indexed in Scilit:
- Plasma metabolomic profiling for hepatocellular carcinoma diagnosis and microvascular invasion predictionInternational Journal of Cancer, 2025
- Loss of Carbamoyl Phosphate Synthetase 1 Potentiates Hepatocellular Carcinoma Metastasis by Reducing Aspartate LevelAdvanced Science, 2024
- Discovery of a Carbamoyl Phosphate Synthetase 1–Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental AnalysisHepatology, 2021
- Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B‐related hepatocellular carcinomaMolecular Carcinogenesis, 2020
- Coffee Drinking and Reduced Risk of Liver Cancer: Update on Epidemiological Findings and Potential MechanismsCurrent Nutrition Reports, 2019
- A Large‐scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinomaHepatology, 2018
- Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cellsCellular and Molecular Life Sciences, 2017
- Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized DataGenetic Epidemiology, 2013
- Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinomaHepatology, 2012
- SAMPLE SIZE DETERMINATION FOR DIAGNOSTIC ACCURACY STUDIES INVOLVING BINORMAL ROC CURVE INDICESStatistics in Medicine, 1997